Vaccine manufacturer Bharat Biotech has signed an licensing agreement with Washington University School of Medicine in St Louis, Missouri, United States to manufacture single-dose intranasal vaccine for the coronavirus, the Hindustan Times reported on Wednesday.
Bharat Biotech owns the rights to distribute the vaccine in all markets except the United States, Japan and Europe, the company announced. United States-based Precision Virologics has also obtained rights to manufacture the vaccine.
The Phase-1 trials will take place in the Washington University School of Medicine’s vaccine and treatment evaluation unit. Bharat Biotech will pursue next stages of clinical trials in India after getting regulatory approval. It will also manufacture large doses of the vaccine at its GMP facility located in Genome Valley, Hyderabad.
“We are proud to collaborate on this innovative…